StockNews.AI
PFE
StockNews.AI
7 days

PADCEV™ Plus KEYTRUDA™ Significantly Improves Survival for Certain Patients with Bladder Cancer When Given Before and After Surgery

1. Pfizer's PADCEV and KEYTRUDA show positive Phase 3 clinical trial results. 2. This may enhance PFE's market position and product portfolio.

2m saved
Insight
Article

FAQ

Why Bullish?

Positive trial results could lead to increased sales and market confidence, resembling past successes like Inlyta's trial results leading to stock surges.

How important is it?

The successful trial indicates potential revenue growth from PADCEV, making this news highly relevant for PFE investors.

Why Short Term?

Immediate market reaction expected as trial results boost investor sentiment, similar to previous drug approvals.

Related Companies

ASTMRKBMY
NEW YORK & TOKYO--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced positive topline results from the Phase 3 EV-303 clinical trial (also known as KEYNOTE-905). The EV-303 study is evaluating PADCEV™ (enfortumab vedotin), a Nectin-4 directed antibody-drug conjugate, in combination with KEYTRUDA™ (pembrolizumab), a PD-1 inhibitor, as neoadjuvant and adjuvant treatment (before and after surgery) versus surge.

Related News